In addition, a more specific CDK4 inhibitor (i.e., PF-07220060) and two more broad CDK4/6 inhibitors (i.e., FLX925 and ETH-155008) are under examination in the context of certain advanced solid tumors and hematologic malignancies. This evidence concerns the gene CDK4 and hematologic disorder.